Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 1/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 1/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 1/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 1/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 1/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 1/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ARG1 | P05089 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selfotel SCHEMBL13431267 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL120234 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL120235 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL20553546 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL16392882 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL9603151 | 0.98 | MEN1 (0.97) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL9602901 | 0.98 | MEN1 (0.97) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| Selfotel SCHEMBL9603159 | 0.98 | MEN1 (0.97) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL13431281 | 0.87 | MEN1 (0.77) | MEN1KMT2AALDH1A1CYP1A2THRB | |
| SCHEMBL5058512 | 0.85 | MEN1 (0.73) | MEN1KMT2AALDH1A1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | claimed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | claimed |
| EP-3441087-A1 | METHODS OF TREATING CHRONIC PAIN | Teva Pharmaceuticals International GmbH (CH) | 2019-02-13 | — | — | EP | claimed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | claimed |
| EP-2265287-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2018-09-05 | — | — | EP | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| WO-1995031986-A1 | COMBINATION PRODUCT OF DICHLOROACETIC ACID AND AN NMDA ANTAGONIST | ASTRA AKTIEBOLAG (SE) | 1995-11-30 | — | — | WO | claimed |
| EP-0533832-A4 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | US COMMERCE (US) | 1993-04-28 | — | — | EP | claimed |
| EP-0533832-A1 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | claimed |
| WO-1991019493-A1 | TREATMENT OF MOOD DISORDERS WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE/NMDA RECEPTOR COMPLEX | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-12-26 | — | — | WO | claimed |
| EP-0432994-A2 | Excitatory amino acid antagonists as anti-emetic drugs | Olney, John William (US) | 1991-06-19 | — | — | EP | claimed |
| EP-0203891-B1 | CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | claimed |
| US-4916125-A | ADMINISTERING E-2-AMINO-4-METHYL-5-PHOSPHONO-3-PENTENOIC ACID | SANDOZ LTD. (CH) | 1990-04-10 | — | — | US | claimed |
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | claimed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | MEN1 3248/4885KMT2A 1669/4885ALDH1A1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.